ABSTRACT Introduction CAR-T therapies for relapsed or refractory (r/r) T-cell lymphoblastic leukemia/lymphoma (T-LL/L) faces challenges, with most clinical studies conducted in small, dispersed cohorts and often reviewed alongside preclinical studies. This review focuses exclusively on clinical studies, evaluating CAR constructs, safety and efficacy. Methods A systematic review was conducted of databases, clinical trial registries, and abstracts from conferences (June 2014 to June 2024). Preclinical studies and studies lacking clinical details were excluded. Data on patient demographics, CAR-T characteristics, response rates, survival, and adverse events were analyzed. Results Eleven CAR-T constructs targeting CD7 and two targeting CD5 were identified. Complete remission (CR/CRi) rates ranged from 55% to 100%, exceeding 80% in most studies. Relapse, often in extramedullary sites, ranged from 7% to 66%. Cytokine release syndrome and neurotoxicity were generally manageable. GVHD incidence varied (none to 60%), primarily in allogeneic CAR-T recipients. Infections contributed to 6–38% of treatment-related mortality. Conclusions CAR-T therapy achieves high response rates in r/r T-LL/L and may serve as a bridge to allogeneic transplantation. However, the short follow-up and the duration of responses remain concerns, and challenges endure, including GVHD, immune recovery and infection control. Standardized reporting is crucial to optimize therapy outcomes and safety in future trials. Registration PROSPERO (CRD420251024662).

CAR-T cell therapy in T-Cell lymphoblastic leukemia/lymphoma: where do we stand now?

Background/Objectives: Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many of them become platelet transfusion-dependent. Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) able to accelerate megakaryopoiesis, which has been used successfully in patients with bone marrow failure and immune thrombocytopenia (ITP). Its role in managing thrombocytopenia and other cytopenias in CAR-T cell-treated patients has been scarcely addressed. Our aim was to report the safety and efficacy of this approach in patients included in the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC) registry. Methods: This is a retrospective, multicenter, observational study. Patients who developed platelet transfusion dependence subsequently to CAR-T cells and received eltrombopag to improve platelet counts were recruited in 10 Spanish hospitals. Results: Thirty-eight patients were enrolled and followed up for a median (interquartile range [IQR]) of 175 (99, 489) days since CAR-T cell infusion. At the moment eltrombopag was indicated, 18 patients had thrombocytopenia and another severe cytopenia, while 8 patients had severe pancytopenia. After 32 (14, 38) days on eltrombopag, 29 (76.3%) patients recovered platelet transfusion independence. The number of platelet units transfused correlated with the time needed to restore platelet counts higher than 20 × 109/L (Rho = 0.639, p &lt; 0.001). Non-responders to eltrombopag required more platelet units (58 [29, 69] vs. 12 [6, 26] in responders, p = 0.002). Nineteen out of twenty-three (82.6%) patients recovered from severe neutropenia after 22 (11, 31) days on eltrombopag. Twenty-nine out of thirty-five (82.9%) patients recovered red blood cell (RBC) transfusion independence after 29 (17, 44) days. Seven patients recovered all cell lineages while on treatment. No thromboembolic events were reported. Only two transient toxicities (cholestasis, hyperbilirubinemia) were reported during eltrombopag treatment, none of which compelled permanent drug withdrawal. Conclusions: Eltrombopag could be safely used to manage thrombocytopenia and accelerate transfusion independence in CAR-T cell-treated patients. 

Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients

Background: Background: CD19 Chimeric Antigen Receptor T cell(CAR-T)therapy has been successfully used to treat refractory/relapse B-cell lymphoma (r/r B-NHL). However,the risk was significantly increased due to gastrointestinal bleeding of CAR-T cell therapy for gastrointestinal (GI) lymphoma. Aims: Aims: To explored the risk factors of GI bleeding and the efficacy of CAR-T cell therapy for GI lymphoma . Methods: Methods: From May 2019 to December 2021,26 patients with r/r B-NHL involvement of the GI tract were enrolled. The male/female ratio was 1.8:1, with a median age of 40.5 years (range, 19-69 years).The diagnosis included diffuse large B-cell lymphoma (DLBCL) (n=21) and Burkitt lymphoma (n=5). All patients were in advanced stage (stage III-IV), and received a median of 7 lines of prior treatment.The disease status was progressive disease (PD)in all patients who failed to multi-line therapies.The median International Prognostic Index (IPI) was 3 (range, 1-4).Most patients (16/26,61.5%) received bridging therapy before CAR T cell infusion.The most common site of involvement was the colonic(10/26,38.5%), followed by small

https://doi.org/10.1097/01.hs9.0000847688.01787.13

P1206: gastrointestinal bleeding significantly reduced the efficacy and survival of cd19 car-t cell therapy in patients with gastrointestinal tract involvement of refractory/relapsed b-cell lymphoma

Background: Background: SCT800 (Omfiloctocog alfa) is the first domestic recombinant factor VIII approved in China based on pivotal study NCT03815318. The extension study (NCT03947567) is ongoing to evaluate the long term safety and efficacy in previously treated patients (≥12 years) with severe hemophilia A. Aims: Aims: To report the interim data for the extension study. Methods: Methods: Patients who completed the main study enrolled in the open ‐ label extension study and continued receiving 25-50 IU/kg SCT800 every other day or three times weekly. The primary endpoint was development of inhibitors; the key secondary endpoints included median annualized bleeding rate (ABR). The interim data demonstrate favorable long-term safety of SCT800 and the maintenance of low ABR in patients with severe hemophilia A.

P1670: long term safety and efficacy of recombinant human coagulation factor viii (sct800) in previously treated patients with severe hemophilia a

Background: Background: The prognosis of refractory/relapsed T-cell lymphoma is extremely poor, especially for the patients who failed to allogeneic hematopoietic stem cell transplantation(allo-HSCT). Aims: Aims: For r/r T-cell lymphoma, a clinical trial using CD7 chimeric antigen receptor T-cell(CD7 CAR-T) has been registered, and the safety and efficacy will be evaluated. Methods: Methods: From August 2017 to January 2022, 10 patients were enrolled. The median age was 32(19-72) years old. The diagnosis included T cell lymphoblastic lymphoma(T-LBL,n=8) ,hepatosplenic T-cell lymphoma(HSTL,n=1)and monomorphic epitheliotropic intestinal T-cell lymphoma(MEITL,n=1). The disease status was progressive disease (PD)in all patients who failed to multi-line therapies, including allo-HSCT (7/10,70%), local irradiation (2/10,20%) .Three patients(3/10, 30%)had central nervous system involvement.In order to further reduce the tumor burden, all patients were treated with bridging therapy before CAR-T cell infusion. Before the trial, the expression of CD7 antigen in tumor tissue was positive confirmed by pathology. Patients received FC regimen (fludarabine and cyclophosphamide) before CAR-T cells infusion. The kinetics and function of CAR-T cells was monitored by quantitative PCR and flow cytometry. The efficacy was evaluated by PET-CT as well as bone marrow puncture every 3 month after CAR-T infusion.

P1236: efficacy and toxicity for cd7 chimeric antigen receptor t-cell therapy in patients with relapsed/refractory t-cell lymphoma

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

F. Yang

Author Tools

Chat about Author

Papers

P1206: gastrointestinal bleeding significantly reduced the efficacy and survival of cd19 car-t cell therapy in patients with gastrointestinal tract involvement of refractory/relapsed b-cell lymphoma

P1670: long term safety and efficacy of recombinant human coagulation factor viii (sct800) in previously treated patients with severe hemophilia a

P1236: efficacy and toxicity for cd7 chimeric antigen receptor t-cell therapy in patients with relapsed/refractory t-cell lymphoma